A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
April 14, 2022
End Date
April 30, 2027
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
April 14, 2022
End Date
April 30, 2027